Top Industry Leaders in the Paroxysmal Supraventricular Tachycardia Market
Latest Paroxysmal Supraventricular Tachycardia (PSVT) Companies Updates:
Milestone Pharmaceuticals (NASDAQ: MIST): Milestone reported positive final results from their Phase 3 RAPID clinical trial testing etripamil for PSVT treatment. The drug met its primary endpoint with statistically significant results, potentially paving the way for FDA approval.
Iterum Therapeutics (NASDAQ: ITUM): Announced positive Phase 2b data for ITR-603, a novel non-stimulant oral medication for treating PSVT. The results showed favorable safety and efficacy, warranting further clinical development.
Medtronic (NYSE: MDT): Launched a clinical trial evaluating their Symplicity® System for treatment of PSVT patients with atrioventricular nodal re-entrant tachycardia (AVNRT), the most common type of PSVT.
Boston Scientific (NYSE: BSX): Received FDA approval for their Farapulse® catheter system, used for catheter ablation treatment of PSVT.
Biotronik (ETR: BIOT): Launched their EnRhythm® Supra system, a next-generation ablation catheter designed for precise PSVT treatment.
Abbott (NYSE: ABT): Received FDA approval for their Navicath Rhythm™ system, a mapping and navigation system for guiding catheter ablation procedures in PSVT treatment.
List of Paroxysmal Supraventricular Tachycardia (PSVT) companies in the market:
- GlaxoSmithKline PLC (U.K.)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S.)
- AstraZeneca PLC (U.K.)
- Teva pharmaceutical industries (Israel)
- Sanofi SA (France)
- Medtronic, Inc. (U.S.)
- Glenmark Pharmaceuticals (U.S.)
- St. Jude Medical, Inc. (U.S.)
- BIOTRONIK SE & Co. KG (U.S.)
- GE Healthcare (U.S.)
- Boston Scientific Corporation (U.S.)
